Alfred G. Gilman is Director at REGENERON PHARMACEUTICALS INC (REGN). They have made 7 open-market trades across 1 company since 2006, most recently 2015-08-06.
CIK 0001225473
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| REGN | SELL | 2015-08-06 | 2015-08-07 | $587.12 | $2.9M | -13.6% | -2.9% | -2.9% |
| REGN | SELL | 2014-11-24 | 2014-11-25 | $408.44 | $16.3M | -13.6% | -2.9% | -2.9% |
| REGN | SELL · 10b5-1 | 2014-02-21 | 2014-02-24 | $340.00 | $1.7M | -13.6% | -2.9% | -2.9% |
| REGN | SELL · 10b5-1 | 2014-02-11 | 2014-02-12 | $320.00 | $1.6M | -13.6% | -2.9% | -2.9% |
| REGN | SELL · 10b5-1 | 2014-01-14 | 2014-01-14 | $300.00 | $1.5M | -13.6% | -2.9% | -2.9% |
| REGN | SELL | 2013-05-06 | 2013-05-08 | $261.04 | $3.9M | -13.6% | -2.9% | -2.9% |
| REGN | SELL | 2012-08-07 | 2012-08-07 | $139.56 | $2.1M | -13.6% | -2.9% | -2.9% |
| REGN | SELL | 2012-02-15 | 2012-02-15 | $109.56 | $2.9M | -13.6% | -2.9% | -2.9% |
| REGN | SELL · 10b5-1 | 2011-05-02 | 2011-05-02 | $50.77 | $1.0M | -13.6% | -2.9% | -2.9% |
| REGN | SELL · 10b5-1 | 2011-03-17 | 2011-03-18 | $38.97 | $66K | -13.6% | -2.9% | -2.9% |
| REGN | SELL · 10b5-1 | 2007-02-26 | 2007-02-28 | $21.55 | $30K | -13.6% | -2.9% | -2.9% |
| REGN | SELL · 10b5-1 | 2007-02-26 | 2007-02-28 | $21.46 | $185K | -13.6% | -2.9% | -2.9% |
| REGN | SELL | 2006-01-06 | 2006-01-10 | $16.18 | $147K | -13.6% | -2.9% | -2.9% |
| REGN | SELL | 2006-01-06 | 2006-01-10 | $16.46 | $15K | -13.6% | -2.9% | -2.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.